Sign In
Buy AZN
$183.02
+2.00 (+1.10%)
At Close: Jun 24, 2026
AstraZeneca Shares Surge After Revenue Beat on Cancer Drug Sales, $1 Billion Pfizer Deal
12:05pm, Friday, 28'th Jul 2023
AstraZeneca's shares rose on Friday after it announced the purchase of Pfizer's rare disease portfolio for up to $1 billion and reported better-than-expected financial results on strong sales of its c
Compared to Estimates, Astrazeneca (AZN) Q2 Earnings: A Look at Key Metrics
11:01am, Friday, 28'th Jul 2023
The headline numbers for Astrazeneca (AZN) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estima
AstraZeneca beats Q2 earnings estimates, sees strong sales of cancer treatment drugs
10:52am, Friday, 28'th Jul 2023
AstraZeneca CFO Aradhana Sarin joins Yahoo Finance Live's Anjalee Khemlani Q2 earnings, the value of gene therapy treatment for rare diseases, the company's guidance regarding China, and expectations
AstraZeneca number show how it is 'not a one-trick pony' - analyst
08:23am, Friday, 28'th Jul 2023
AstraZeneca PLC's (LSE:AZN) underlying quarterly performance shows it is "far from a one-trick pony" and its share price premium over peers is entirely warranted, broker Shore Capital said. Alongsid
AstraZeneca CFO: Geopolitics is not playing a role in doing business in China
05:20am, Friday, 28'th Jul 2023
AstraZeneca CFO Aradhana Sarin says the company's China business has provided growth and innovation opportunities and is in a "unique space" that allows it to swerve geopolitical tensions.
AstraZeneca CFO denies geopolitics impacts the company's China business after spinoff rumors
05:07am, Friday, 28'th Jul 2023
Aradhana Sarin told CNBC the company was in a "very unique space" regarding impact from rising geopolitical tensions between China and the west.
AstraZeneca CEO says lung cancer drug trial data 'very encouraging'
04:59am, Friday, 28'th Jul 2023
AstraZeneca Chief Executive Pascal Soriot said on Friday the company is "very encouraged" by interim data from a key lung cancer drug trial, but he did not explain why the company had not declared res
AstraZeneca unit strikes $1bn rare diseases deal with Pfizer
02:41am, Friday, 28'th Jul 2023
AstraZeneca PLC's rare disease unit, Alexion, has unveiled a $1 billion agreement to acquire Pfizer's early-stage gene therapy portfolio, a strategic move designed to bolster its footprint in the bur
AstraZeneca signs $1 bln deal with Pfizer for gene therapy portfolio
02:16am, Friday, 28'th Jul 2023
AstraZeneca said on Friday its unit Alexion has agreed to buy a portfolio of U.S. drugmaker Pfizer's early-stage rare disease gene therapy for up to $1 billion, plus royalties on sales.
AstraZeneca second quarter profit beats expectations
02:13am, Friday, 28'th Jul 2023
AstraZeneca on Friday beat expectations for its second-quarter profit, helped by better-than-expected sales of its oncology drugs.
NatWest adjusts to life after Rose, plus AstraZeneca and BA interims due on Friday
11:01am, Thursday, 27'th Jul 2023
A month ago NatWest Group PLC (LSE:NWG) would have expected a fairly calm set of interim results focusing on its UK and investment banking divisions. That was before Nigel Farage's Coutts account
Why AstraZeneca (AZN) Might Surprise This Earnings Season
10:12am, Thursday, 27'th Jul 2023
AstraZeneca (AZN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
AstraZeneca share price: death cross nears ahead of earnings
04:17pm, Wednesday, 26'th Jul 2023
AstraZeneca (LON: AZN) share price has struggled in the past few weeks as concerns about its cancer drug. After soaring to a record high of 12,350 in April, the stock has plunged by ~14% to 10,650, me
Big Pharma bets on China's aging population
04:09pm, Monday, 24'th Jul 2023
Certain industries have reduced their presence and or reliance on the Chinese market in 2023, but Big Pharma isn't one of them, according to reporting from the Wall Street Journal. The company's agi
AstraZeneca PLC (AZN) is Attracting Investor Attention: Here is What You Should Know
10:05am, Monday, 24'th Jul 2023
Recently, Zacks.com users have been paying close attention to Astrazeneca (AZN). This makes it worthwhile to examine what the stock has in store.
